Moderna, Inc. (MRNA)

24.21 0.05 (0.21%)

As of 2025-12-02 08:32:58 EST

Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Traded asNasdaq: MRNA
ISINUS60770K1079
CIK0001682852
LEI549300EI6OKH5K5Q2G38
EIN813467528
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOStéphane Bancel
Employees5,800
Fiscal Year End1231
Address325 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone6177146500
Websitehttp://modernatx.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
MRNAModerna, Inc.2025-12-02 08:32:5824.210.050.21
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
MRNA0001682852Moderna, Inc.US60770K1079549300EI6OKH5K5Q2G38813467528Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE325 BINNEY STREETCAMBRIDGEMA02142UNITED STATESUS6177146500325 BINNEY STREET, CAMBRIDGE, MA, 02142325 BINNEY STREET, CAMBRIDGE, MA, 02142Moderna Therapeutics, Inc.Biotechnology2010Stéphane Bancel5,800http://modernatx.com42,100,000,000391,000,000390,679,512Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".2025-11-27 15:32:55
This is a preview of the latest data. Subscribe to access the full data.
MRNA Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
MRNA Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202442,100,000,0001,900,000,0004.7264385,815,8773,742,6690.9796
202340,200,000,000-8,600,000,000-17.623382,073,208-4,266,386-1.1043
202248,800,000,000-32,000,000,000-39.604386,339,594-16,533,392-4.1039
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Shannon Thyme KlingerChief Legal Officer, Corporate Secretary2024829,468011,507,317763,77615,52517,368,701
Stephen HogePresident20241,083,92304,422,6981,447,99215,5259,181,478
Stéphane BancelChief Executive Officer20241,625,88507,654,7301,965,600975,21319,876,180
Arpa GarayChief Commercial Officer2023842,30801,460,282619,65063,4134,445,948
James MockChief Financial Officer2023792,30801,460,282583,20021,1004,317,185
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20245,800
20235,600
20223,900
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue3,236,000,0006,848,000,00019,263,000,000
Cost Of Revenue1,464,000,0004,693,000,0005,416,000,000
Gross Profit———
Research And Development Expenses4,543,000,0004,845,000,0003,295,000,000
General And Administrative Expenses1,174,000,0001,549,000,0001,132,000,000
Operating Expenses7,181,000,00011,087,000,0009,843,000,000
Operating Income-3,945,000,000-4,239,000,0009,420,000,000
Net Income-3,561,000,000-4,714,000,0008,362,000,000
Earnings Per Share Basic-9.28-12.3321.26
Earnings Per Share Diluted-9.28-12.3320.12
Weighted Average Shares Outstanding Basic384,000,000382,000,000394,000,000
Weighted Average Shares Outstanding Diluted384,000,000382,000,000416,000,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents1,927,000,0002,907,000,0003,205,000,000
Marketable Securities Current5,098,000,0005,697,000,0006,697,000,000
Accounts Receivable358,000,000892,000,0001,385,000,000
Inventories117,000,000202,000,000949,000,000
Non Trade Receivables72,000,00019,000,00036,000,000
Other Assets Current58,000,00088,000,00065,000,000
Total Assets Current8,099,000,00010,325,000,00013,431,000,000
Marketable Securities Non Current2,494,000,0004,677,000,0008,318,000,000
Property Plant And Equipment———
Other Assets Non Current594,000,000685,000,000988,000,000
Total Assets Non Current6,043,000,0008,101,000,00012,427,000,000
Total Assets14,142,000,00018,426,000,00025,858,000,000
Accounts Payable405,000,000520,000,000487,000,000
Deferred Revenue153,000,000568,000,0002,038,000,000
Short Term Debt———
Other Liabilities Current221,000,00066,000,000249,000,000
Total Liabilities Current2,206,000,0003,015,000,0004,923,000,000
Long Term Debt———
Other Liabilities Non Current267,000,000256,000,000135,000,000
Total Liabilities Non Current1,035,000,0001,557,000,0001,812,000,000
Total Liabilities3,241,000,0004,572,000,0006,735,000,000
Common Stock000
Retained Earnings10,045,000,00013,606,000,00018,320,000,000
Accumulated Other Comprehensive Income-10,000,000-123,000,000-370,000,000
Total Shareholders Equity10,901,000,00013,854,000,00019,123,000,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization185,000,000617,000,000348,000,000
Share Based Compensation Expense429,000,000305,000,000226,000,000
Other Non Cash Income Expense-60,000,000-7,000,000-28,000,000
Change In Accounts Receivable-534,000,000-493,000,000-1,790,000,000
Change In Inventories-83,000,000-747,000,000-492,000,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-69,000,00013,000,000240,000,000
Change In Other Liabilities78,000,00073,000,00088,000,000
Cash From Operating Activities-3,004,000,000-3,118,000,0004,981,000,000
Purchases Of Marketable Securities6,529,000,0003,760,000,00011,435,000,000
Sales Of Marketable Securities3,967,000,0003,206,000,0003,548,000,000
Acquisition Of Property Plant And Equipment1,051,000,000707,000,000400,000,000
Acquisition Of Business085,000,000—
Other Investing Activities———
Cash From Investing Activities1,949,000,0004,206,000,000-5,176,000,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock66,000,00046,000,0000
Repurchase Of Common Stock01,153,000,0003,329,000,000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities56,000,000-1,377,000,000-3,448,000,000
Change In Cash-999,000,000-289,000,000-3,643,000,000
Cash At End Of Period1,927,000,0002,907,000,0003,205,000,000
Income Taxes Paid197,000,000-357,000,0002,729,000,000
Interest Paid24,000,00039,000,00025,000,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-9.28-12.3321.26
Price To Earnings Ratio-4.4806-8.06578.4487
Earnings Growth Rate-24.7364-157.9962-29.8581
Price Earnings To Growth Ratio0.18110.051-0.283
Book Value Per Share28.38836.26748.5355
Price To Book Ratio1.46472.74223.7008
Ebitda-3,179,000,000-4,454,000,00011,439,000,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures———
Free Cash Flow———
Return On Equity-0.3267-0.34030.4373
One Year Beta1.45971.02721.5679
Three Year Beta1.41921.21620.5347
Five Year Beta0.62810.62040.6016
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Hoge StephenPresident2025-11-28610A1,454,864
Hoge StephenPresident2025-11-28295D1,454,569
Hoge StephenPresident2025-11-28610D3,053
Klinger Shannon ThymeChief Legal Officer2025-11-28329A28,898
Klinger Shannon ThymeChief Legal Officer2025-11-28160D28,738
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Rob Bresnahan2025-05-08PA08Sale2025-04-08—$1,001 - $15,000
Rob Bresnahan2025-03-27PA08Purchase2025-02-25—$1,001 - $15,000
Julie Johnson2025-02-12TX32Sale2025-01-15Joint$1,001 - $15,000
Josh Gottheimer2024-03-07NJ05Sale2024-02-01Joint$1,001 - $15,000
Josh Gottheimer2023-10-15NJ05Sale2023-09-15Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
DEERFIELD MANAGEMENT COMPANY, L.P.2025-09-3025,830,0001,000,00025.83
Man Group plc2025-09-302,001,82577,50025.83
Man Group plc2025-09-301,743,52567,50025.83
Man Group plc2025-09-3030,785,3051,191,84325.83
CITADEL ADVISORS LLC2025-09-30155,623,1676,024,90025.83
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Investment Managers Series Trust II2025-09-30Class KFORKX1654,261.950.0052
Investment Managers Series Trust II2025-09-30Class IFORTX1654,261.950.0052
PRAXIS FUNDS2025-09-30Praxis Small Cap Index Fund Class IMMSIX10,250264,757.50.1328
PRAXIS FUNDS2025-09-30Praxis Small Cap Index Fund Class AMMSCX10,250264,757.50.1328
RYDEX SERIES FUNDS2025-09-30Class CRYCFX44,7821,156,719.061.2851
This is a preview of the latest data. Subscribe to access the full data.